Interaction between glucagon and Hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans

European Journal of Endocrinology

Volumn 143, Issue 5, 2000, Pages 601-606

  Arvat, E ^a   Maccagno, B ^a   Ramunni, J ^a   Giordano, R ^a   Broglio, F ^a   Gianotti, L ^a   Maccario, M ^a   Camanni, F ^a   Ghigo, E ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCAGON; GROWTH HORMONE; HEXARELIN; HYDROCORTISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CORTICOTROPIN RELEASE; DRUG POTENTIATION; FEMALE; FLUSHING; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; HYPOPHYSIS ADRENAL SYSTEM; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN INTERACTION; SOMNOLENCE;

EID: 0033663717     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430601     Document Type: Article

References (57)

1. Growth-hormone release by glucagon
2. Glucagon stimulation of human growth hormone
3. Growth hormone response to intramuscular glucagon
4. A preview of growth hormone stimulation tests in children
5. Subcutaneous glucagon as a test of the ability of the pituitary to secrete GH and ACTH
6. Intramuscular glucagon as a provocative stimulus for the assessment of pituitary function: Growth hormone and cortisol responses
7. A comparison of the insulin tolerance/glucagon test with the short ACTH stimulation test in the assessment of the hypothalamo-pituitary-adrenal axis in the early post-operative period after hypophysectomy
8. Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test
9. Hypoglycemia: A potent stimulus to secretion of growth hormone
10. Glucagon-induced growth hormone release in children
11. Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity
12. About the effects of glucagon on growth hormone release. Letter to the editor
13. ACTH-releasing effect of glucagon in humans Interaction with hCRH, AVP and Hexarelin
14. Atypical growth hormone releasing peptides
15. Small peptides as potent releasers of growth hormone
16. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release
17. Growth hormone (GH)-releasing peptides
18. Peptidomimetic regulation of growth hormone secretion
19. Growth hormone secretagogues as corticotrophin-releasing factors
20. Ipamorelin, the first selective growth hormone secretagogue
21. Hexarelin, a synthetic growth hormone-releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adenocorticotropin and cortisol secretion in humans
22. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH, and hCRH
23. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome
24. The effect of an opiate antagonist on the hormonal changes induced by hexarelin
25. Corticotropin-releasing hormone in humans
26. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites
27. A receptor in pituitary and hypothalamus that functions in growth hormone release
28. 125I-p-benzoyl-phenylalanine Hexarelin derivative
29. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland
30. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
31. Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for growth hormone secretagogue receptor
32. Pituitary adenylate cyclase acting polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors
33. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action
34. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamo-pituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level
35. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6
36. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation
37. Selective lack of growth hormone (GH) response to the GH-releasing peptide Hexarelin in patients with GH-releasing hormone receptor deficiency
38. Activation of the hypothalamo-pitiutary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats
39. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin
40. The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants
41. The effect of Hexarelin on growth hormone (GH) secretion in patients with GH deficiency
42. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in puberal children and in adults but not in prepuberal children and in elderly subjects
43. Effect of propranonol on the response of serum growth hormone to glucagon
44. Growth hormone response to propranolol-glucagon stimulation: A comparison with other test of growth hormone reserve
45. Modulation of growth hormone-releasing activity of hexarelin in man
46. Interaction of the growth hormone releasing peptide hexarelin with somatostatin
47. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
48. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: Comparison with insulin-induced hypoglycemia test
49. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection
50. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man
51. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6
52. A non-peptidyl GH secretagogue
53. In vitro characterization of four novel classes of growth hormone-releasing peptide
54. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors
55. Repeated administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels
56. Increases in circulating insulin-like growth factor-I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation
57. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans